Dutch biotech rais­es €30M for up­scaled man­u­fac­tur­ing, pi­lot study of blood clot­ting drug

Var­mX, a Dutch biotech de­vel­op­ing a re­ver­sal agent for blood thin­ners, has bagged a €30 mil­lion Se­ries B2 round as it gets ready to launch a piv­otal tri­al.

Spun out of the lab of founder Pieter Re­its­ma at Lei­den Uni­ver­si­ty Med­ical Cen­ter, the com­pa­ny’s lead com­pound, VMX-C001, is de­signed to re­verse the ef­fects of car­dio­vas­cu­lar drugs that pre­vent blood clots — so that pa­tients who are on those drugs can stop bleed­ing when they need to.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN